#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions

Months after capmatinib — the MET inhibitor designed to cross the blood-brain barrier discovered by Incyte and licensed by Novartis — secured the FDA’s priority review in patients with a form of lung cancer, the Swiss drugmaker has reported encouraging, albeit early, data in patients whose cancer had spread to the brain.